JP2017522273A5 - - Google Patents

Download PDF

Info

Publication number
JP2017522273A5
JP2017522273A5 JP2016570242A JP2016570242A JP2017522273A5 JP 2017522273 A5 JP2017522273 A5 JP 2017522273A5 JP 2016570242 A JP2016570242 A JP 2016570242A JP 2016570242 A JP2016570242 A JP 2016570242A JP 2017522273 A5 JP2017522273 A5 JP 2017522273A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016570242A
Other languages
English (en)
Japanese (ja)
Other versions
JP6768522B2 (ja
JP2017522273A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/034281 external-priority patent/WO2015187998A2/en
Publication of JP2017522273A publication Critical patent/JP2017522273A/ja
Publication of JP2017522273A5 publication Critical patent/JP2017522273A5/ja
Application granted granted Critical
Publication of JP6768522B2 publication Critical patent/JP6768522B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016570242A 2014-06-04 2015-06-04 Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用 Active JP6768522B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462007702P 2014-06-04 2014-06-04
US62/007,702 2014-06-04
PCT/US2015/034281 WO2015187998A2 (en) 2014-06-04 2015-06-04 Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020066803A Division JP2020125302A (ja) 2014-06-04 2020-04-02 Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用

Publications (3)

Publication Number Publication Date
JP2017522273A JP2017522273A (ja) 2017-08-10
JP2017522273A5 true JP2017522273A5 (https=) 2018-07-12
JP6768522B2 JP6768522B2 (ja) 2020-10-14

Family

ID=54767596

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016570242A Active JP6768522B2 (ja) 2014-06-04 2015-06-04 Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
JP2020066803A Pending JP2020125302A (ja) 2014-06-04 2020-04-02 Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020066803A Pending JP2020125302A (ja) 2014-06-04 2020-04-02 Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用

Country Status (5)

Country Link
US (2) US10300074B2 (https=)
EP (1) EP3151920B1 (https=)
JP (2) JP6768522B2 (https=)
CA (1) CA2950911C (https=)
WO (1) WO2015187998A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9546174B2 (en) 2012-11-30 2017-01-17 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (IAP) antagonists
CN105451726B (zh) * 2013-06-25 2021-03-16 沃尔特和伊利莎豪医学研究所 治疗细胞内感染的方法
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2015187998A2 (en) 2014-06-04 2015-12-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
CN113453678A (zh) * 2018-11-26 2021-09-28 德彪药业国际股份公司 Hiv感染的联合治疗
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
AR117206A1 (es) * 2018-11-30 2021-07-21 Glaxosmithkline Ip Dev Ltd Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer
CN110028508B (zh) * 2019-05-16 2021-05-28 南京华威医药科技集团有限公司 一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂
CA3148504A1 (en) 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
WO2021060477A1 (ja) * 2019-09-26 2021-04-01 富士フイルム株式会社 皮膚感作性測定試薬、皮膚感作性の測定方法、及び化合物
CA3160666A1 (en) * 2019-11-08 2021-05-14 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (iap) protein antagonists
WO2021222614A1 (en) * 2020-04-30 2021-11-04 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (iap) protein antagonists
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
AR131299A1 (es) 2022-12-09 2025-03-05 Debiopharm Int Sa Nuevos inhibidores de iap, métodos para fabricarlos y usos de los mismos
EP4712960A2 (en) * 2023-05-15 2026-03-25 Recludix Pharma, Inc. Stat degraders and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5457196A (en) 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
US5455242A (en) 1991-09-27 1995-10-03 Merrell Dow Pharmaceuticals Inc. Carboxyalkyl tricyclic derivatives useful as inhibitors of enkephalinase and ace
AU673857B2 (en) 1992-10-30 1996-11-28 Aventisub Ii Inc. Mercaptoacetylamide bicyclic lactam derivatives
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
ATE415413T1 (de) 2002-07-15 2008-12-15 Univ Princeton Iap-bindende verbindungen
US7932382B2 (en) 2004-01-16 2011-04-26 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
CN1926118A (zh) 2004-03-01 2007-03-07 德克萨斯大学董事会 二聚的小分子细胞凋亡增强剂
WO2005094818A1 (en) 2004-03-23 2005-10-13 Genentech, Inc. Azabicyclo-octane inhibitors of iap
RS52545B (sr) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
BRPI0511350A (pt) 2004-07-02 2007-12-04 Genentech Inc composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
EP1773348A4 (en) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
MX2007007195A (es) 2004-12-20 2007-10-08 Genentech Inc Inhibidores de pirrolidina de iap.
ES2456671T3 (es) 2005-02-25 2014-04-23 Tetralogic Pharmaceuticals Corporation Inhibidores diméricos de IAP
JP2008545780A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 有機化合物
WO2007041775A1 (en) 2005-10-10 2007-04-19 The University Of Queensland Cysteine protease inhibitors incorporating azide groups
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
JP5230610B2 (ja) 2006-05-05 2013-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 二価ｓｍａｃ模倣物およびその使用
KR20090086244A (ko) 2006-12-07 2009-08-11 노파르티스 아게 증식성 질환의 치료에서의 6-옥소-1,6-디히드로피리미딘-2-일
US20090010941A1 (en) * 2007-04-09 2009-01-08 University Of Massachusetts Methods for treating HIV
JP5454943B2 (ja) 2007-04-12 2014-03-26 ジョイアント ファーマスーティカルズ、インク． 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体
WO2008128171A2 (en) 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
PE20130150A1 (es) 2007-04-30 2013-02-27 Genentech Inc Inhibidores de las iap
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers
EP2265604A4 (en) 2008-04-11 2011-10-26 Univ Michigan HETEROARYL-SUBSTITUTED BICYCLIC SMAC MIMETICA AND ITS APPLICATIONS
EP2519664A4 (en) * 2009-12-30 2014-03-12 Avila Therapeutics Inc LIGAND-RELATED COVALENTS MODIFYING A PROTEIN
PE20121524A1 (es) 2010-01-27 2012-12-03 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapeuticos
WO2012125622A1 (en) 2011-03-14 2012-09-20 Bristol-Myers Squibb Company Substituted adipic acid amides and uses thereof
IN2014KN02774A (https=) * 2012-06-06 2015-05-08 Bionor Immuno As
US9546174B2 (en) 2012-11-30 2017-01-17 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (IAP) antagonists
WO2015187998A2 (en) 2014-06-04 2015-12-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy

Similar Documents

Publication Publication Date Title
JP2017522273A5 (https=)
ES2746374T3 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección producida por el virus del VIH
RU2013119607A (ru) Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний
CO2019008531A2 (es) Análogos de atazanavir (atv) para tratar infecciones por vih.
JP2015520769A5 (https=)
RU2018137389A (ru) Гетероциклические амиды, полезные в качестве модуляторов
JP2016533379A5 (https=)
RU2017124136A (ru) Трициклическое спиро-соединение
JP2016501223A5 (https=)
JP2016179996A5 (https=)
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
JP2013209405A5 (https=)
JP2009536620A5 (https=)
JP2016506962A5 (https=)
JP2016509047A5 (https=)
RU2003110577A (ru) Гетероциклические соединения, связывающиеся с хемокиновыми рецепторами
JP2014511891A5 (https=)
JP2015509983A5 (https=)
RU2012148758A (ru) Лизинспецифические ингибиторы деметилазы-1 и их применение
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
JP2017523225A5 (https=)
JP2017531619A5 (https=)
JP2019501879A5 (https=)
JP2019505529A5 (https=)
JP2018522861A5 (https=)